Evogene Ltd. (TLV:EVGN)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 18.05M -50.7% |
| Revenue (ttm) | 5.82M -72.7% |
| Net Income | -37.16M |
| EPS | -4.32 |
| Shares Out | 10.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,001 |
| Open | 173.30 |
| Previous Close | 173.30 |
| Day's Range | 173.30 - 173.60 |
| 52-Week Range | 115.10 - 478.70 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 18, 2026 |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses... [Read more]
Financial Performance
In 2025, Evogene's revenue was $3.85 million, a decrease of -30.91% compared to the previous year's $5.58 million. Losses were -$8.49 million, -48.53% less than in 2024.
Financial numbers in USD Financial StatementsNews
Evogene Q2 2026 Deep Dive: EPS Beats, Revenue Down 35%
Evogene Ltd. delivered a surprise narrowing of its quarterly loss, beating consensus expectations by 50% despite posting a 35% revenue decline. The biotechn... The post Evogene Q2 2026 Deep Dive: EPS ...
Evogene Q2 Loss Narrows As AI Transformation Drives Strategic Progress
(RTTNews) - Evogene Ltd. (EVGN) reported second-quarter and first-half 2026 financial results, highlighting continued progress in its transformation into a focused, AI-driven computational chemistry c...
Evogene Earnings Call Transcript: Q2 2026
Transformed into a focused AI-driven company, achieving major cost reductions and operational milestones. Q2 net loss improved 62% year-over-year, with strong progress in pharma and ag collaborations. Cash usage remains disciplined, and new board members are planned.
Evogene Earnings release: Q2 2026
Evogene released its Q2 2026 earnings on August 18, 2026, summarizing the period's financial results.
Evogene Reports Second Quarter and First Half 2026 Financial Results
Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product devel...
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside
Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
Zoom conference call scheduled for August 18, 2026, at 9:00 AM ET REHOVOT, Israel, Aug. 14, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemist...
Evogene Schedules Second Quarter 2026 Financial Results Release
Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry,...
Evogene (EVGN) Partners with ELEO for PCSK9 Inhibitor Development
Evogene (EVGN) Partners with ELEO for PCSK9 Inhibitor Development
Evogene and ELEO announce scientific collaboration
Evogene (EVGN) and ELEO, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, announced a strategic scientific collaboration to ...
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases
Collaboration combines Evogene's AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billio...
AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success at early discovery stages REHOVOT, Israel, July 15, 2026 /PRNe...
Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation
Evogene (EVGN) Partners with Tel Aviv University for Drug Discovery Innovation
Evogene, BCDD announces strategic joint initiative
Evogene (EVGN) and the Blavatnik Center for Drug Discovery, BCDD, at Tel Aviv University announced a strategic joint initiative aimed at accelerating the growth, development, and success of innovation...
Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
Supporting Israel's Academic Innovation Ecosystem: BCDD to Provide World-Class Experimental Infrastructure, Evogene to Deliver Computational Chemistry and AI Capabilities REHOVOT, ISRAEL and TEL AVIV,...
Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud
Evogene (EVGN) Achieves Milestone in Collaboration with Google Cloud
Evogene achieves integration of agentic systems with ChemPass AI platform
Evogene (EVGN) announced the successful completion of a significant milestone in its second collaboration with Google (GOOG) Cloud. This milestone marks the integration of agentic computational system...
Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
Integration of agentic computational systems enables the early-stage definition of key clinical and biological success criteria, accelerating discovery timelines, improving scalability, and increasing...
Evogene Slides: Company presentation
Evogene has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry s...
Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results
Evogene (EVGN) Completes Phase 1 Trial of BMC128 with Promising Results
Evogene says Phase 1 clinical study of BMC128 met primary endpoint
Evogene (EVGN) announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd., in co...
Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a p...
Evogene price target lowered to $2.15 from $2.25 at Alliance Global
Alliance Global lowered the firm’s price target on Evogene (EVGN) to $2.15 from $2.25 and keeps a Buy rating on the shares. Evogene reported Q1 results that were within the…
Evogene Q1 2026 Loss Deepens: -$0.60/Share vs -$0.28 Expected
Miss Across Metrics. Evogene Ltd. (NASDAQ:EVGN) delivered disappointing Q1 2026 results that fell short of Wall Street expectations, reporting a loss per sh... The post Evogene Q1 2026 Loss Deepens: -...